ST2 pathogenetic profile in ambulatory heart failure patients

Journal of Cardiac Failure

Volumn 21, Issue 4, 2015, Pages 355-361

  Bayes Genis, Antoni ^a   Januzzi, James L ^b   Gaggin, Hanna K ^b   De Antonio, Marta ^a   Motiwala, Shweta R ^b   Zamora, Elisabet ^a   Galán, Amparo ^a   Domingo, Mar ^a   Urrutia, Agustín ^a   Lupón, Josep ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

biomarkers; Heart failure; prognosis

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; GALECTIN 3; PROTEIN; ST2 PROTEIN; TROPONIN T; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CELL SURFACE RECEPTOR; IL1RL1 PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

AGED; ARTICLE; CARDIOVASCULAR RISK; CONGESTIVE CARDIOMYOPATHY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NEW YORK HEART ASSOCIATION CLASS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL RATE; ADULT; BLOOD; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; INCIDENCE; METABOLISM; OUTPATIENT; PATHOPHYSIOLOGY; PROGNOSIS; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; TRENDS; UNITED STATES;

ADULT; BIOMARKERS; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; INCIDENCE; MALE; MYOCARDIUM; NATRIURETIC PEPTIDE, BRAIN; OUTPATIENTS; PEPTIDE FRAGMENTS; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, CELL SURFACE; RECEPTORS, INTERLEUKIN-1; RISK ASSESSMENT; ROC CURVE; SURVIVAL RATE; UNITED STATES; VENTRICULAR FUNCTION, LEFT;

EID: 84926609870     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2014.10.014     Document Type: Article

References (35)

1. C.W. Yancy, M. Jessup, B. Bozkurt, J. Butler, D.E. Casey Jr., and M.H. Drazner American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation 128 2013 e240 e327
2. J.L. Mitcham, P. Parnett, T.P. Bonnert, K.E. Garka, M.J. Gerhart, and J.L. Slack T1/ST2 signaling establishes it as a member of an expanding interleukin-1 receptor family J Biol Chem 271 1996 5777 5783
3. L.A.J. O'Neill, and C.A. Dinarello The IL-1 receptor/Toll-like receptor superfamily: crucial receptors for inflammation and host defense Immunol Today 21 2000 206 209
4. D. Xu, W.L. Chan, B.P. Leung, R. Wheeler, D. Piedrafita, and J.H. Robinson Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells J Exp Med 187 1998 787 794
5. H2 effector function Proc Natl Acad Sci U S A 95 1998 6930 6935
6. K. Yanagisawa, Y. Naito, K. Kuroiwa, T. Arai, Y. Furukawa, and H. Tomizuka The expression of ST2 gene in helper T cells and the binding of ST2 protein to myeloma-derived RPMI8226 cells J Biochem 121 1997 95 103
7. S. Sanada, D. Hakuno, L.J. Higgins, E.R. Schreiter, A.N.J. McEnzie, and R.T. Lee IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system J Clin Invest 117 2007 1538 1549
8. M. Shimpo, D.A. Morrow, E.O. Weinberg, M.S. Sabatine, S.A. Murphy, and E.M. Antman Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction Circulation 109 2004 2186 2190
9. E.O. Weinberg, M. Shimpo, G.W. de Keulenaer, C. MacGillivray, S. Tominaga, and S.D. Solomon Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction Circulation 106 2002 2961 2966
10. E.O. Weinberg, M. Shimpo, S. Hurwitz, S. Tominaga, J.L. Rouleau, and R.T. Lee Identification of serum soluble ST2 receptor as a novel heart failure biomarker Circulation 107 2003 721 726
11. J.L. Januzzi Jr. ST2 as a cardiovascular risk biomarker: from the bench to the bedside J Cardiovasc Transl Res 6 2013 493 500
12. J.L. Januzzi Jr., S. Rehman, A.A. Mohammed, A. Bhardwaj, L. Barajas, and J. Barajas Use of amino-terminal pro-B type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction J Am Coll Cardiol 58 2011 1881 1889
13. R.W. Troughton, C.M. Frampton, T.G. Yandle, E.A. Espiner, M.G. Nicholls, and A.M. Richards Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations Lancet 355 2000 1126 1130
14. J.J. Park, D.J. Choi, C.H. Yoon, I.Y. Oh, E.S. Jeon, J.J. Kim KorHF Registry Prognostic value of C-reactive protein as an inflammatory and N-terminal probrain natriuretic peptide as a neurohumoral marker in acute heart failure (from the Korean Heart Failure registry) Am J Cardiol 113 2014 511 517
15. J. Dumic, S. Dabelic, and M. Flögel Galectin-3: an open-ended story Biochim Biophys Acta 1760 2006 616 635
16. A. Krzéslak, and A. Lipinska Galectin-3 as a multifunctional protein Cell Mol Biol Lett 9 2004 305 328
17. M. de Antonio, J. Lupón, A. Galán, J. Vila, A. Urrutia, and A. Bayes-Genis Combined use of high-sensitivity cardiac troponin T and NT-proBNP improves measurements of performance over established mortality risk factors in chronic heart failure Am Heart J 163 2012 821 828
18. A. Bayes-Genis, M. de Antonio, J. Vila, J. Peñafiel, A. Galán, and J. Barallat Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3 J Am Coll Cardiol 63 2014 158 166
19. A. Bhardwaj, S.U. Rehman, A. Mohammed, A.L. Baggish, S.A. Moore, and J.L. Januzzi Jr. Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study Am Heart J 159 2010 532 538.e1
20. R. Kakkar, and R.T. Lee The IL-33/ST2 pathway: therapeutic target and novel biomarker Nat Rev Drug Discov 7 2008 827 840
21. B. Ky, B. French, K. McCloskey, J.E. Rame, E. McIntosh, and P. Shahi High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure Circ Heart Fail 4 2011 180 187
22. A. Bayes-Genis, M. de Antonio, A. Galán, H. Sanz, A. Urrutia, and R. Cabanes Combined use of highsensitivity ST2 and NTproBNP to improve the prediction of death in heart failure Eur J Heart Fail 14 2012 32 38
23. G.M. Felker, M. Fiuzat, V. Thompson, L.K. Shaw, M.L. Neely, and K.F. Adams Soluble ST2 in ambulatory patients with heart failure: Association with functional capacity and long-term outcomes Circ Heart Fail 6 2013 1172 1179
24. D.A. Pascual-Figal, J. Ordoñez-Llanos, P.L. Tornel, R. Vázquez, T. Puig, and M. Valdés MUSIC Investigators. Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction J Am Coll Cardiol 54 2009 2174 2179
25. D.L. Mann Mechanisms and models in heart failure: a combinatorial approach Circulation 100 1999 999 1008
26. F. Liang, and D.G. Gardner Mechanical strain activates BNP gene transcription through a p38/NF-κB-dependent mechanism J Clin Invest 104 1999 1603 1612
27. S. Tominaga A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor FEBS Lett 258 1989 301 304
28. K. Yanagisawa, T. Takagi, T. Tsukamoto, T. Tetsuka, and S. Tominaga Presence of a novel primary response gene ST2L, encoding a product highly similar to the interleukin 1 receptor type 1 FEBS Lett 318 1993 83 87
29. S. Kumar, M.D. Minnich, and P.R. Young ST2/T1 protein functionally binds to two secreted proteins from Balb/c 3T3 and human umbilical vein endothelial cells but does not bind interleukin 1 J Biol Chem 270 1995 27905 27913
30. M.A. Gayle, J.L. Slack, T.P. Bonnert, B.R. Renshaw, G. Sonoda, and T. Taguchi Cloning of a putative ligand for the T1/ST2 receptor J Biol Chem 271 1996 5784 5789
31. J. Diez, A. Gonzalez, B. Lopez, and R. Querejeta Mechanisms of disease: pathologic structural remodeling is more than adaptive hypertrophy in hypertensive heart disease Nat Clin Pract Cardiovasc Med 2 2005 209 216
32. T. Baudino, W. Carver, W.R. Giles, and T.K. Borg Cardiac fibroblasts: friend or foe? Am J Physiol Heart Circ Physiol 291 2006 H1015 H1026
33. A.A. Chackerian, E.R. Oldham, E.E. Murphy, J. Schmitz, S. Pflanz, and R.A. Kastelein IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex J Immunol 179 2007 2551 2555
34. U.C. Sharma, S. Pokgarel, T.J. van Brakel, J.H. van Berlo, J.P. Cleutjens, and B. Schroen Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction Circulation 110 2004 3121 3128
35. J. Lupón, M. de Antonio, A. Galán, J. Vila, E. Zamora, and A. Urrutia Combined use of the novel biomarkers high-sensitivity troponin T and ST2 for heart failure risk stratification vs conventional assessment Mayo Clin Proc 88 2013 234 243